Key result
Pitavastatin 4 mg plus diet effectively manages severe hyperlipidemia in high-risk type 2 diabetes.
Why the study?
Management of lipid storage disease in patients with diabetes mellitus and high cardiovascular risk requires evaluation of effective and safe therapies such as Pitavastatin.
Case Report (n=1)
Review supports Pitavastatin consideration in diabetic hyperlipidemia; leaves open need for dedicated outcome trials.
The review article presents data on the management of lipid storage disease in patients with diabetes mellitus (DM). A clinical case of a patient with diabetes and high cardiovascular risk caused by severe hyperlipidemia among other things is provided for illustrative purposes. The article reviews the results of clinical studies of the efficacy and safety of Pitavastatin in patients with cardiometabolic disorders. The dynamics of the lipid spectrum and glycaemia indicators against the background of course therapy with Pitavastatin at a daily dose of 4 mg in combination with the diet therapy is monitored in patients with diabetes.
No takes yet. Share an insight, caveat, or question.
Мамедов et al. (2018) conducted a case report in Type 2 diabetes mellitus and severe hyperlipidemia (n=1). Pitavastatin was evaluated on Dynamics of the lipid spectrum and glycaemia indicators. A clinical case illustrates the use of pitavastatin 4 mg daily combined with diet therapy for managing severe hyperlipidemia in a patient with type 2 diabetes mellitus and high cardiovascular risk.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: